Umecrine Mood announces positive results from an

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD)

Most women experience some form of premenstrual symptoms but in about five percent of young and middle-aged women that have PMDD, the symptoms are so debilitating that they affect normal daily life, work and relationships. The severity of the symptoms confers huge costs on society.

Umecrine Mood’s candidate drug UC1010 is a first-in-class therapy for PMDD.  UC1010 has been developed specifically to target the atypical effects of progesterone metabolites on GABA-A receptor activity in the brain, believed to underlie key PMDD symptoms.

In an exploratory double blind, randomized multicenter study, 120 patients with PMDD received placebo or one of two doses of UC1010 during one menstrual cycle. The objectives of the trial were to study the safety and efficacy of UC1010.  The primary efficacy end-point was assessed using a validated daily rating scale (DRSP), to measure the average late luteal phase symptoms in patients treated with UC1010 vs. those given placebo. As previously reported, the primary efficacy end-point of the study was not met.

Following final analysis of the study data, we report here that UC1010 elicits a highly statistically significant reduction of symptoms in PMDD patients that have taken the drug according to the intended treatment regimen.  The post-hoc analysis revealed two key variables that impacted the study outcome:

  1. Despite patient randomization, the baseline follicular phase symptoms showed a skewed distribution between study groups.  Recalculation of results to correct for individual follicular symptoms reveals a statistically significant improvement of symptoms by UC1010 compared to placebo in the total study population (p<0.05 for the total premenstrual symptom score).  
  2. More significantly, due to inconsistencies in the assessment of ovulation, 32% of patients did not receive treatment as intended according to the protocol.  Inclusion only of patients treated as intended shows there were highly significant beneficial effects of UC1010 (both doses) compared to placebo, both for the cardinal PMDD symptoms (p=0.003) and total premenstrual symptom scores (p=0.006) as well as for the impairment score (p=0.01), which specifically measures the impact of symptoms on daily life in the week prior to menstruation.

There were no safety concerns with UC1010 and it was well tolerated.  

Marie Bixo, Principle Investigator, said: “These results are very encouraging and well in line with effects seen in other studies (using antidepressants), with the added bonus that UC1010 is safe and well tolerated, with none of the side-effects seen with other agents used for PMDD treatment”.

Karin Ekberg, CEO of Umecrine Mood, commented: “This exploratory Phase I/II trial is the first to show a beneficial effect of a novel mechanism-based therapy to treat a condition affecting a large proportion of women. We have learned some important lessons from this initial study and are now well-positioned to move forward to conduct a definitive Phase II clinical trial”.

Note: Karolinska Development owns 38% of Umecrine Mood including indirect ownership through KDev Investments AB, KCIF Co-Investment Fund KB and Umecrine AB.

 

For further information, please contact: Karin Ekberg, CEO, Umecrine Mood AB Phone: +46 8 524 844 82, e-mail: karin.ekberg@umecrine.se

Torbjörn Bjerke, CEO, Karolinska Development AB Phone: +46 727 444 123, e-mail: torbjorn.bjerke@karolinskadevelopment.com

 

TO THE EDITORS

About Umecrine Mood AB Umecrine Mood is developing novel products to treat symptoms associated with premenstrual dysphoric disorder (PMDD), a debilitating condition that affects 3-8% of women worldwide. The company’s lead candidate drug is a first-in-class compound, currently in Phase II clinical development that inhibits the negative effects of progesterone metabolites on key mood pathways in the brain. For more information, please visit www.umecrine.se/mood

About Karolinska Development AB Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 33 projects, of which 16 are in clinical development. For more information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
s?page=2">More News Articles